-
Neuropsychiatric Disease and Treatment
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Hypoglycemia associated with insulin hypersecretion following the addition of olanzapine to conventional antipsychotics
(2533) Views (471) Full article downloads
Authors: Takahiko Nagamine
Published Date February 2006
Volume 2006:2(4) Pages 583 - 585
DOI: http://dx.doi.org/10.2147/NDT.S
Takahiko Nagamine
Division of Psychiatric Internal Medicine, Seiwakai-Kitsunan Hospital, Suzenji, Japan
Abstract: After a violent episode, a 47-year-old Japanese man with chronic treatment-resistant schizophrenia was admitted to our hospital and treated with conventional antipsychotics. After 3 years, olanzapine was added. Four days later, he lost consciousness and blood tests revealed marked hypoglycemia, increased insulin levels, and a homeostasis model assessment of insulin resistance of 2.5. He recovered rapidly after intravenous injection of glucose. He had no history of loss of consciousness, was not obese and did not have any risk factors for hypoglycemia. Similar episodes occurred in the early morning of the fifth and sixth days following the olanzapine administration. Each time there was the same response to intravenous glucose. Olanzapine was discontinued on the seventh day and, after one year, replaced by risperidone. Since then (2 years ago), his schizophrenic symptoms have been in partial remission and he has had no further hypoglycemic episodes. In view of the possible induction of hypoglycemia with olanazapine, even in the absence of any risk factors, and in the absence of any major differences in efficacy, it is a reasonable strategy to select an agent such as risperidone which has more favorable sideeffect profile.
Keywords: metabolic syndrome, hypoglycemia, insulin resistance, schizophrenia, secondgeneration antipsychotics
Readers of this article also read:
Serum substance P levels in patients with chronic schizophrenia treated with typical or atypical antipsychotics
Abnormal laboratory values during the acute and recovery phases in schizophrenic patients: a retrospective study
Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia
Editorial
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Corrigendum
Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia
Erratum
A case of recurrent bloody tears
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- Journal Indexing
See where all the Dove Press journals are indexed
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor
- Implementing the 2009 Institute of Medicine recommendations on resident physician work hours, supervision, and safety
- Moderate alcohol consumption and cognitive risk
- Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference




